Illumina (NASDAQ:ILMN) Updates FY 2025 Earnings Guidance

Illumina (NASDAQ:ILMN) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 4.760-4.790 for the period. The company issued revenue guidance of $4.3 billion-$4.3 billion. Illumina also updated its Q4 2025 guidance to 1.270-1.300 EPS.

Illumina Stock Up 0.5%

NASDAQ ILMN traded up $0.71 during trading hours on Tuesday, reaching $146.26. 857,805 shares of the company traded hands, compared to its average volume of 1,752,380. The stock has a market capitalization of $22.35 billion, a PE ratio of 32.84, a PEG ratio of 2.35 and a beta of 1.41. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. Illumina has a 12 month low of $68.70 and a 12 month high of $153.06. The company has a 50 day moving average of $130.52 and a two-hundred day moving average of $110.24.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The company’s revenue for the quarter was up .4% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities analysts expect that Illumina will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Evercore ISI reaffirmed an “outperform” rating and set a $155.00 price target on shares of Illumina in a report on Monday, January 5th. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Cowen reiterated a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Barclays increased their price target on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. Finally, Robert W. Baird set a $109.00 price objective on shares of Illumina in a research note on Friday, October 31st. Five analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $122.56.

Insider Activity at Illumina

In related news, Director Scott Gottlieb bought 500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were acquired at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the acquisition, the director directly owned 12,523 shares of the company’s stock, valued at $1,529,433.99. The trade was a 4.16% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. State Street Corp lifted its stake in Illumina by 6.8% in the third quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock valued at $569,800,000 after acquiring an additional 382,520 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Illumina by 3.1% during the 3rd quarter. AQR Capital Management LLC now owns 3,398,027 shares of the life sciences company’s stock valued at $315,915,000 after purchasing an additional 102,147 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Illumina by 1.9% in the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after purchasing an additional 35,167 shares during the last quarter. Invesco Ltd. boosted its holdings in Illumina by 3.1% in the third quarter. Invesco Ltd. now owns 1,395,255 shares of the life sciences company’s stock worth $132,507,000 after purchasing an additional 42,178 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in Illumina by 1.8% in the third quarter. Legal & General Group Plc now owns 1,244,688 shares of the life sciences company’s stock worth $118,208,000 after purchasing an additional 21,565 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.